We are studying the safety and effects of YTB323 in patients with treatment-resistant generalized myasthenia gravis. This research aims to understand how the drug works in the body and its potential to improve symptoms.
Health conditions and diseases that the clinical trial is designed to study and treat.
Myasthenia Gravis (MG) is a chronic autoimmune disorder that causes weakness in the skeletal muscles, which are responsible for breathing and moving parts of the body. In its treatment-resistant form, patients may find it difficult to manage symptoms despite standard treatments.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.